Feature		Gender			Hospitalization status			Age				Disease outcome		
		Male	Female	Ρ	ICU	Non-ICU	Ρ	<30	30–60	>60	Ρ	Recovery	Death	Ρ
Final diagnosis: frequency (%)	Pityrasis rosea like	1 (6.3)	0 (0)	0.4	0 (0)	1 (4.8)	0.4	0 (0)	1 (6.3)	0 (0)	0.5	1 (5)	0 (0)	0.14
	Herpes labialis	1 (6.3)	1 (7.7)		0 (0)	2 (9.5)		0 (0)	1 (6.3)	1 (8.3)		2 (10)	0 (0)	
	Herpes zoster	0 (0)	2 (15.4)		1 (14.3)	1 (4.8)		0 (0)	2 (12.5)	0 (0)		1 (5)	0 (0)	
	Maculopapular viral exanthema	2 (12.5)	1 (7.7)		1 (14.3)	1 (4.8)		0 (0)	2 (12.5)	0 (0)		2 (10)	0 (0)	
	Drug reaction	1 (6.3)	2 (15.4)		0 (0)	3 (14.3)		0 (0)	0 (0)	3 (25.0)		2 (10)	0 (0)	
	Livedo reticularis/ rasemoca	1 (6.3)	3 (23.1)		2 (28.6)	2 (9.5)		1 (100)	2 (12.5)	2 (16.7)		1 (5)	3 (50)	
	Acral peeling	4 (25.0)	0 (0)		0 (0)	4 (19.0)		0 (0)	3 (18.8)	1 (8.3)		3 (15)	1 (16.7)	
	Contact dermatits	1 (6.3)	2 (15.4)		2 (28.6)	1 (4.8)		0 (0)	1 (6.3)	2 (16.7)		1 (5)	1 (16.7)	
	Urticarial viral rash	2 (12.5)	0 (0)		0 (0)	2 (9.5)		0 (0)	1 (6.3)	1 (8.3)		2 (10)	2 (33.3)	
	Other	3 (18.8)	2 (15.4)		1 (14.3)	5 (19.0)		0 (0)	3 (18.8)	2 (16.7)		5 (25)	5 (83.3)	

Table 2 Final diagnosis of skin lesions in different genders, age groups, hospitalization statuses and disease outcomes

and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All patients or their legal guardians signed informed consent regarding publishing their data and photographs.

P. Ramezani Darmian,¹ Z. Memarzadeh,¹ R. Aryan,¹ Y. Nahidi,¹ Z. Mehri,¹ A. Taghipour,² N. Samimi,³ M. Amini,⁴ P. Layegh^{1,*}

¹Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran, ²Health Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran, ³Department of Dermatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, ⁴Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran *Correspondence: P. Layegh. E-mail: layeghpo@mums.ac.ir

References

- 1 Huang C, Wang Y, Li X *et al*. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497–506.
- 2 Rostami A, Sepidarkish M, Leeflang M *et al*. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. *Clin Microbiol Infect* 2021; 27: 331–340.
- 3 Xydakis MS, Dehgani-Mobaraki P, Holbrook EH et al. Smell and taste dysfunction in patients with COVID-19. Lancet Infect Dis 2020; 20: 1015–1016.
- 4 Chi G, Lee JJ, Jamil A *et al.* Venous thromboembolism among hospitalized patients with COVID-19 undergoing thromboprophylaxis: a systematic review and meta-analysis. *J Clin Med* 2020; **9**: 2489.
- 5 Majadas S, Pérez J, Casado-Espada NM, Zambrana A, Bullón A, Roncero C. A case with psychotic disorder as a clinical presentation of COVID-19. *Psychiatry Clin Neurosci* 2020; **74**: 551–552.
- 6 Alramthan A, Aldaraji W. Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East. *Clin Exp Dermatol* 2020; 45: 746–748.

DOI: 10.1111/jdv.17557

Retiform purpura and extensive skin necrosis as the single manifestation of SARS-CoV-2 infection

Dear Editor,

It is known that dermatological manifestations of SARS-CoV-2 infection are heterogeneous and have been a subject of increasing discussion. Most common clinical patterns include maculopapular rash, perniosis, urticaria, vesicular eruption, livedo reticularis and retiform purpura.^{1–3} The latter has been exclusively described in critically ill patients, often requiring invasive ventilation for massive pulmonary involvement.^{4–6} Retiform purpura can arise in additional circumstances, such as calciphylaxis, cutaneous vasculitis, purpura fulminans and warfarin-induced necrosis.⁷ We report a case of SARS-CoV-2 infection with associated extensive necrotic retiform purpura and no other organ involvement.

A 44-year-old man sought our emergency department due to the appearance of large (>15 cm) patches with retiform configuration and central necrosis, predominantly involving both thighs, compatible with retiform purpura (Fig. 1). The lesions appeared a week before and had progressively worsened despite treatment with oral prednisolone. He was otherwise asymptomatic, with no fever. Peripheral oxygen saturation was 98% on room air. His past medical history included only untreated type 2 diabetes mellitus. There was no history of previous medications, such as warfarin, or illegal drugs, including cocaine. Initial workup revealed minor leucocytosis and slightly elevated C-reactive protein (10 mg/L) and D-dimers (354 ng/dL). Haemoglobin levels, platelet count, renal function, liver enzymes and coagulation studies were normal. Although otherwise symptomless, a nasopharyngeal polymerase chain reaction for SARS-



Figure 1 Skin findings at presentation, showing large plaques with retiform configuration and central necrosis affecting both thighs. (a) Lateral aspect of the right thigh; (b) anterior aspect of both thighs; and (c) lateral aspect of the left thigh.

CoV-2 test was made as a routine procedure, which rendered a positive result.

The patient was admitted for 12 days for further investigation and monitoring of skin and other potential manifestations of disease. Oral prednisolone dose was increased, and therapeutic enoxaparin was started. Additional laboratory investigations revealed only increased glycosylated haemoglobin levels (7.7%), elevated erythrocyte sedimentation rate (59 mm/h) and positive antinuclear antibodies. Phospho-calcium and parathyroid hormone levels, antiphospholipid, anticardiolipin and antineutrophil cytoplasmic antibodies, C3 and C4 levels, cryoglobulin and fibrinogen were normal. Investigation for congenital and acquired thrombophilias, urinalysis and chest X-ray were unremarkable. Urine cocaine levels were negative. A skin biopsy revealed thrombosis of small and medium calibre vessels of the dermis and hypodermis, consistent with thrombotic vasculopathy, without fibrinoid necrosis, calcium deposits or infectious agents. Direct immunofluorescence revealed deposits of fibrinogen, IgG, IgM and C1a. Throughout admission, all previously diagnosed lesions stabilized, and no additional signs or symptoms of other organ involvement were observed.

The patient was discharged and has been receiving regular dressing care in our department, three times per week, with remarkable evolution (Fig. 2). Initially, necrotic tissue was removed through mechanical and enzymatic debridement. The subsequent ulcer has been under local treatment with povidone–iodine-containing dressing with polyethylene glycol base.

Retiform purpura in COVID-19 has been exclusively described in critically ill patients with multisystemic severe

disease.^{4–6,8,9} In this case, retiform purpura with extensive skin necrosis was the presenting and single manifestation of SARS-CoV-2 infection, with no pulmonary or additional impairment. Laboratorial findings were unspecific and excluded other possible causes of such cutaneous findings. Histological features were similar to previous cases of COVID-19-associated retiform purpura. Uncontrolled diabetes mellitus could be a risk factor for such extensive disease, but the paucity of other clinical and laboratorial findings further corroborates the heterogeneous outcomes of SARS-CoV-2 infection.

Acknowledgements

The patient in this manuscript has given written informed consent to the publication of their case details.

Conflict of interest

Margarida Brito Caldeira, Mafalda Pestana, Ana Luísa João, Cândida Fernandes, Alexandre João and Nélia Cunha have no conflicts of interest to declare.

Funding souerces

The authors received no financial support for the authorship or publication of this article.

M. Brito Caldeira*, D M. Pestana, D A.L. João, D C. Fernandes, A. João, N. Cunha Dermatology and Venereology Department, Centro Hospitalar Universitário de Lisboa Central, E.P.E., Lisbon, Portugal *Correspondence. M. Brito Caldeira. E-mail: margaridabcaldeira@

gmail.com



Figure 2 Skin findings at 6 weeks of treatment, showing central ulcer with granulation tissue and surrounding epithelization area and wound contraction, maintaining original configuration. (a) Lateral aspect of the right thigh and (b) lateral aspect of the left thigh.

References

- Genovese G, Moltrasio C, Berti E, Marzano AV. Skin Manifestations associated with COVID-19: current knowledge and future perspectives. *Dermatology* 2021; 237: 1–12.
- 2 Avila J, Long B, Holladay D, Gottlieb M. Thrombotic complications of COVID-19. *Am J Emerg Med* 2021; **39**: 213–218.
- 3 Galván Casas C, Català A, Carretero Hernández G et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183: 71–77.
- 4 Çabuk FK, Sakiz D. Necrotizing skin findings in coronavirus disease 2019: a case report. *Iran J Pathol* 2021; **16**: 79–83.
- 5 Becker RC. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis 2020; **50**: 499–511.
- 6 Magro CM, Mulvey JJ, Laurence J et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol 2021; 184: 141–150.
- 7 Wysong A, Venkatesan P. An approach to the patient with retiform purpura. Dermatol Ther 2011; 24: 151–172.
- 8 Bosch-Amate X, Giavedoni P, Podlipnik S et al. Retiform purpura as a dermatological sign of coronavirus disease 2019 (COVID-19) coagulopathy. J Eur Acad Dermatol Venereol 2020; 34: e548–e549.
- 9 García-Irigoyen A, Acatitla-Acevedo GA, Barrera-Godínez A, Méndez-Flores S, Domínguez-Cherit J. Follow-up of dermatological

manifestations in non-critical hospitalized patients with COVID-19 pneumonia and their prognostic correlation with disease severity. *J Eur Acad Dermatol Venereol* 2021; **35**: e421–e423.

DOI: 10.1111/jdv.17562

Cutaneous reactions to inactivated SARS-CoV-2 vaccine and ChAdOx1-S (recombinant) vaccine against SARS-CoV-2: a case series from the Philippines

Dear Editor,

The Philippines remains one of the countries with the highest number of new COVID-19 cases in the Western Pacific region.¹